细胞疗法改善心力衰竭患者的生活质量:第三阶段临床试验的结果
Satsuki Yamada1, Jozef Bartunek2, Thomas J Povsic3
1Department of Cardiovascular Medicine, Center for Regenerative Medicine, Marriott Heart Disease Research Program, Van Cleve Cardiac Regenerative Medicine Program, Mayo Clinic, Rochester, MN, USA.
Stem cells translational medicine
|November 25, 2023
概括
心脏形成引导细胞疗法改善了心力衰竭患者的生活质量,特别是那些晚期左心室扩大患者. 这种细胞疗法也减少了响应性小组的死亡和住院.
科学领域:
- 心脏病学 心脏病学
- 再生医学是一种再生医学.
- 临床试验 临床试验
背景情况:
- 心力衰竭严重影响患者的日常活动和生活质量.
- 传统的结局,如死亡和住院,并没有完全捕捉到患者的体验.
- 与健康相关的生活质量 (HRQoL) 的监测对于全面评估心力衰竭至关重要.
研究的目的:
- 评估心脏构造导向细胞疗法在改善缺血性心力衰竭患者的HRQoL方面的有效性.
- 评估细胞治疗对生活质量的影响,使用明尼苏达州心力衰竭问卷 (MLHFQ).
- 为了确定可能特别受益于细胞治疗的患者亚群,关于HRQoL.
主要方法:
- 进行了一项跨国,随机,双盲临床试验 (CHART-1).
- 患有缺血性心力衰竭和左心室喷射分数减少的患者接受细胞治疗或假手术.
- 在基线和整个1年的随访期间,MLHFQ被用于测量HRQoL.
主要成果:
- 总的来说,细胞治疗和假装组在MLHFQ得分上表现出可比的改善.
- 在晚期左心室扩大 (平均差异 -6.4点,P=.009) 患者中,细胞治疗比假药治疗显著优越.
- 在这个响应的子群体中,改善的MLHFQ得分与减少的死亡率和住院率并行 (调整后的曼-惠特尼几率为1.43,P=.039).
结论:
- 心脏形成引导的细胞疗法可能对特定的心力衰竭患者群体有好处,特别是改善生活质量.
- 患有晚期左心室扩大症的患者代表了对细胞治疗有反应的亚群.
- 需要进一步的研究来探索细胞治疗对心力衰竭症状缓解和改善HRQoL的潜力.
相关概念视频
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...